Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Date:8/5/2009

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia (CAP).

In the double-blind study, radezolid was administered orally at three different doses: 300 mg once daily (QD), 450 mg QD and 450 mg twice daily (BID). This novel oxazolidinone showed comparable efficacy across all three doses, with clinical cure rates in the clinically evaluable population ranging from 78% to 92%. Radezolid also showed excellent activity against a number of key CAP pathogens including Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae and atypical respiratory pathogens. Additionally, radezolid was well tolerated, with the most commonly reported adverse events being mild gastrointestinal upset. No hematological adverse events were reported in this study.

"We are extremely encouraged by the positive results we've seen in this Phase 2 trial of radezolid in community-acquired pneumonia," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "Together with the previously reported positive results of the Phase 2 trial in uncomplicated skin infections, we are confident in the potential for radezolid to offer a safe therapeutic alternative for the treatment of methicillin-resistant Staphylococcus aureus and other bacterial infections. Radezolid has been shown to be efficacious and appears to have a favorable safety profile compared to other oxazolidinone compounds. We are looking forward to progressing the development of radezolid with the intravenous formulation in a more complicated disease setting."


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Improve Farmer ... Productivity, ... Ltd. (BWK) today announced the,formation of a joint venture to accelerate ... tolerance and efficient nutrient,utilization to improve the performance of important crops ...
... PPHM ), a clinical stage biopharmaceutical,company developing monoclonal ... (HCV) infection, today announced that it will release its,financial ... on December,10, 2007 at 7:00 a.m. EST and will ... at 11:30 a.m. EST on the same day., ...
... atomic force microscope, the tiny structures look like fragments ... fullerene molecules that are linked together by means of ... for threading these nanopearls in the latest issue of ... molecules made of 60 carbon atoms whose linkages resemble ...
Cached Biology Technology:DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 2DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 3Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results 2
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... most critical of its life. Having run the gauntlet of air ... voyager must also evade hungry fish patrolling the beaches in its ... coral cays the risks are high: as many as 30% perish ... this headlong dash through the waves cost the intrepid hatchlings? Curious ...
... to a sticky scientific problem in basic fluid mechanics: ... rate, but instead forms what look like fingers of ... "gravity fingers," and the explanation for their formation has ... any liquidmeets the soil (or other medium). Knowing how ...
... University Belfast is playing a major role in a 4m ... in food and animal feed. Professor Chris Elliott, Director ... will lead a team of scientists in developing new tests ... a wide range of foods including meat, poultry, milk, seafood ...
Cached Biology News:Cost of hatchling turtles' dash for freedom 2MIT researchers explain mystery of gravity fingers 2Queen's University Belfast plays leading role in Europe-wide tests for safer food 2
... Tecan provides labware carriers to suit ... encountered in the life science laboratory. Labware ... on the worktable. Mounting is simple for ... system that ensures carriers are correctly guided ...
... Protea is pleased to introduce its new ... of lyophilized standard proteins for use in ... laboratories. Proteas Protein Standards are high ... calibration of protein analyses by electrospray ionization ...
Determine relative degree of protein binding to phosphoinositides...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Biology Products: